MESA Alliance's blog
Over the past decades, Research and Development has played a key role in driving the achievements made against malaria with the development of tools such as rapid diagnostic tests (RDTs), artemisinin-combination therapies (ACTs) and long-lasting insecticide-treated nets (LLINs). We have also made great progress in our capacity to disseminate the scientific information to the malaria community; open access journals, webs, blogs, twitter, emails, conferences, publications, etc. However, one of the questions that remained pending was, “is it possible to track all current research projects focused on malaria elimination and eradication?”
MESA is very excited to be launching its new website and knowledge management tools at ASTMH in New Orleans on November 2nd!
The Second Global Malaria Action Plan (GMAP2) will cover the timeframe 2016-2025.
You are strongly encouraged to have a look and contribute by sharing your vision for a malaria-free world.
Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.
Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.
Cambodia is moving towards eliminating malaria. According to the WHO World Malaria Report, less than 100 deaths were attributable to malaria in 2012 (World Malaria Report 2013).